Boehringer Buys Antibody-Drug Conjugates Biotech NBE For €1.18bn
Second Acquisition In ROR1 Space In A Month
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
